Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $260,225.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Gilead Sciences Stock Performance

NASDAQ:GILD traded down $0.08 during trading hours on Friday, hitting $109.95. 9,729,048 shares of the company traded hands, compared to its average volume of 7,379,648. The stock has a market capitalization of $137.03 billion, a price-to-earnings ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $111.03. The firm has a 50-day moving average of $95.41 and a 200 day moving average of $88.73. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is currently 832.43%.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after purchasing an additional 841,776 shares in the last quarter. FMR LLC grew its holdings in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Finally, Norges Bank bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $1,789,254,000. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on GILD. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Truist Financial increased their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a report on Friday, November 8th. UBS Group increased their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.